Drug Profile
Research programme: cancer therapeutics - Myrexis
Alternative Names: MPC-0767; MPI-0479605; MPI-479605; MPI-487109; MPI-487901; MPYS 197; MPYS 413Latest Information Update: 27 Feb 2014
Price :
$50
*
At a glance
- Originator Myriad Pharmaceuticals
- Developer Myrexis
- Class Purines; Small molecules
- Mechanism of Action HSP90 heat-shock protein inhibitors; Phosphotransferase inhibitors; Protein-serine-threonine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 27 Feb 2014 Discontinued - Preclinical for Cancer in USA (PO)
- 09 Nov 2012 The Board of Directors of Myrexis announces a plan of complete liquidation and dissolution of the company
- 11 May 2012 MPC 0767 is available for out-licensing; Myrexis does not intend to further develop the compound itself (\www.myrexis.com\)